10-Q: Ocular Therapeutix Secures $445M, Advances Key Retinal Trials

Ocular Therapeutix reports Q3 2025 financial results, highlighting a significant capital raise and continued progress in its late-stage retinal disease clinical programs for AXPAXLI.

Summary

• Net loss for the three months ended September 30, 2025, was $69.4 million, compared to $36.5 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $201.3 million, compared to $145.1 million for the same period in 2024.
• Product revenue, net, from DEXTENZA decreased by 5.2% to $14.5 million for Q3 2025 and by 16.8% to $38.6 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• Research and development expenses increased by $15.3 million to $52.4 million for Q3 2025 and by $59.7 million to $146.3 million for the nine months ended September 30, 2025, primarily due to the progression of AXPAXLI clinical trials.
• Selling and marketing expenses increased by $2.5 million to $13.1 million for Q3 2025 and by $10.2 million to $41.0 million for the nine months ended September 30, 2025, driven by team expansion and corporate branding.
• General and administrative expenses increased by $3.8 million to $16.0 million for Q3 2025 and by $0.6 million to $46.7 million for the nine months ended September 30, 2025.
• In-Market Sales for DEXTENZA increased to approximately 48,000 units in Q3 2025, up 6,000 units from Q3 2024 and 4,000 units from Q2 2025.
• The SOL-R Phase 3 trial for wet AMD achieved its randomization target of 555 subjects on November 4, 2025.
• A notice of allowance for a U.S. patent covering methods of treating ocular diseases with AXPAXLI was received in September 2025, with the patent issuing in October 2025 and expiring in 2044.
• The company completed an underwritten offering in October 2025, raising approximately $445.4 million in net proceeds.
• Existing cash and cash equivalents of $344.8 million as of September 30, 2025, combined with the October 2025 offering proceeds, are expected to fund operations into 2028.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and DEXTENZA revenue declined, the successful $445.4 million capital raise significantly strengthens its financial position, extending the cash runway into 2028. Strong progress in late-stage clinical trials for AXPAXLI (SOL-1, SOL-R) and the planned initiation of new Phase 3 trials (HELIOS-2, HELIOS-3) with FDA agreement on novel endpoints are major positive developments for the pipeline. The patent allowance for AXPAXLI also adds value. The DEXTENZA revenue decline is a concern, but the increase in in-market units suggests underlying demand. The overall picture is one of a company making substantial progress in its pipeline, backed by a strong financial injection, despite ongoing operational losses.

Positives

• Successfully completed an underwritten offering in October 2025, raising approximately $445.4 million in net proceeds, significantly extending the cash runway.
• Cash and cash equivalents of $344.8 million as of September 30, 2025, combined with recent capital raise, are projected to fund operations into 2028, providing substantial financial stability.
• The SOL-R Phase 3 clinical trial for wet AMD achieved its randomization target of 555 subjects on November 4, 2025, indicating strong progress in a key registrational trial.
• FDA has agreed that the SOL-R trial design, with a primary endpoint at Week 56, is appropriate for supporting a potential New Drug Application (NDA) for AXPAXLI for wet AMD.
• Retention in the SOL-1 trial for wet AMD remains outstanding, with greater than 95% of randomized subjects remaining on-trial, and no safety signals identified by the independent data and safety monitoring committee.
• Received a notice of allowance from the USPTO in September 2025 for a patent covering methods of treating ocular diseases with AXPAXLI, which issued in October 2025 and extends intellectual property protection until 2044.
• Plans to initiate two superiority registrational trials (HELIOS-2 and HELIOS-3) for AXPAXLI in non-proliferative diabetic retinopathy (NPDR) imminently, targeting a broad label including non-center-involved DME.
• FDA provided written agreement under a Special Protocol Assessment (SPA) for the overall design of the HELIOS-2 clinical trial, including a novel ordinal primary endpoint, which is expected to enable smaller, shorter, and less expensive trials with a higher probability of success.
• In-Market Sales for DEXTENZA increased to approximately 48,000 units in Q3 2025, demonstrating growing demand despite revenue challenges.

Negatives

• Net loss significantly increased to $69.4 million for Q3 2025 from $36.5 million in Q3 2024, and to $201.3 million for the nine months ended September 30, 2025, from $145.1 million in the prior year period.
• Product revenue, net, from DEXTENZA decreased by 5.2% for Q3 2025 and by 16.8% for the nine months ended September 30, 2025, primarily due to Medicare reimbursement caps, rebates, discounts, and MIPS inclusion.
• Total costs and operating expenses increased substantially by $21.8 million to $83.2 million for Q3 2025 and by $71.1 million to $239.0 million for the nine months ended September 30, 2025.
• Research and development expenses saw a significant increase, reflecting higher costs associated with advancing multiple clinical trials.
• The company has an accumulated deficit of $1,092.4 million as of September 30, 2025, and expects to continue generating operating losses and negative cash flows in the foreseeable future.
• The cash projection into 2028 does not include the full expenses anticipated to support the commercialization of AXPAXLI, if approved, indicating further significant capital needs will arise.

Risks

• Dependence on successful completion of significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval for product candidates.
• Uncertainty of market acceptance and commercial viability of products, even if successfully developed and approved.
• Reliance on a small number of third-party manufacturers for product supply, with potential adverse effects from significant interruptions.
• Exposure to risks common in the biotechnology industry, including new technological innovations, protection of proprietary technology, dependence on key personnel, and compliance with government regulations.
• Need to obtain additional capital to finance operations, with no assurance of obtaining such financing on acceptable terms or at all, which could force delays or termination of programs.
• Potential for significant changes in costs and timing associated with product development if regulatory authorities require additional trials or if enrollment delays occur.
• Fluctuations in the fair value of derivative liabilities, which are subject to unobservable inputs and estimation methodologies, could materially affect financial estimates.
• The Barings Credit Facility includes covenants, such as maintaining a minimum liquidity amount of $20.0 million, and a pledge of assets as collateral, which may limit the ability to obtain additional debt or other financing.
• Future payments of interest under the Barings Credit Agreement depend on the Secured Overnight Financing Rate (SOFR), and royalty fees depend on future DEXTENZA revenue, both of which are uncertain.

Future Outlook

The company expects research and development expenses to increase significantly as it progresses with the SOL-1 and SOL-R trials, initiates the planned SOL-X, HELIOS-2, and HELIOS-3 trials, and performs increased pre-commercial manufacturing activities for AXPAXLI. Personnel costs are also expected to rise due to additional hiring for clinical trials. Selling and marketing expenses are anticipated to increase to support DEXTENZA commercialization and prepare for the potential commercial launch of AXPAXLI. General and administrative expenses are also projected to increase to strengthen functions supporting clinical trials. The company believes its current cash resources, including the recent capital raise, will fund operations into 2028, covering planned operating expenses, debt service, and capital expenditures, but this does not include full commercialization expenses for AXPAXLI.

Management Comments

• We believe that clinicians are adjusting to the impact of MIPS, and together with our increased sales efforts directed towards HOPDs, which receive separate payment for DEXTENZA in 2025 after being ineligible for separate payments in 2024, we expect DEXTENZA unit growth to continue.
• We continue to expect topline results for the SOL-1 trial to be available in the first quarter of 2026 after the completion of the Week 52 visits for all subjects in the trial.
• On November 4, 2025, we announced that the SOL-R trial has achieved its randomization target of 555 subjects. We will continue to allow randomization of previously enrolled subjects currently in the loading phase of the trial to maintain our commitment to both patients and investigators, with topline data remaining on track for the first half of 2027.
• If we obtain favorable results from the SOL-1 trial and the SOL-R trial, we plan to submit an NDA with the FDA for marketing approval of AXPAXLI for the treatment of wet AMD.
• We believe AXPAXLI has the potential to be the first product for wet AMD with a superiority label as compared to a single injection of anti-VEGF based on the SOL-1 trial, with redosing potentially as infrequently as every 12 months.
• We believe the ordinal DRSS endpoint enables a higher probability of success with smaller, shorter, more relevant, and less expensive trials, relative to other potential endpoints.
• We are currently evaluating next steps for the OTX-TIC program.
• Based on our current operating plan... we believe that our existing cash and cash equivalents... together with the net proceeds from the 2025 Offering, will enable us to fund our planned operating expenses, debt service obligations and capital expenditure requirements into 2028.

Industry Context

Ocular Therapeutix operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on ophthalmic diseases. The company's ELUTYX hydrogel technology positions it in the sustained-release drug delivery segment, aiming to reduce the burden of frequent injections for chronic eye conditions like wet AMD and diabetic retinopathy. The planned use of a novel ordinal primary endpoint in the HELIOS trials for NPDR could set a new standard for efficiency in diabetic retinopathy clinical trials, potentially influencing how other companies design their studies. The challenges faced by DEXTENZA with Medicare reimbursement caps and MIPS inclusion reflect broader pressures on drug pricing and reimbursement within the U.S. healthcare system, impacting commercial success even for approved products.

Comparison to Industry Standards

• The SOL-R trial's non-inferiority design for AXPAXLI 450 µg dosed every 24 weeks against aflibercept 2 mg dosed every eight weeks aims to demonstrate a significant advantage in dosing frequency, potentially surpassing current anti-VEGF standards like Eylea (aflibercept) which typically requires more frequent injections.
• The company's ambition for AXPAXLI to achieve a 'superiority label' over a single injection of anti-VEGF based on the SOL-1 trial, with potential redosing as infrequently as every 12 months, would represent a significant advancement over existing treatments that often require monthly or bi-monthly injections.
• The novel ordinal primary endpoint of 2 or more steps on the DRSS for the HELIOS trials in NPDR is a departure from historical binary endpoints in DR trials. This approach, agreed upon with the FDA, is designed to allow for smaller, shorter, and less expensive trials, potentially offering a more efficient development pathway compared to traditional trial designs used by competitors in the diabetic eye disease space.
• The decrease in DEXTENZA's net product revenue, attributed to Medicare reimbursement caps and MIPS inclusion, highlights the ongoing challenges in the U.S. market for ophthalmic products, where companies like Regeneron (Eylea) and Novartis (Lucentis, Beovu) also navigate complex reimbursement landscapes, though with established market positions and broader product portfolios.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any material legal proceedings, nor are any material legal proceedings threatened against the company to the knowledge of management.

Related Party Transactions

• Incurred fees of $23,000 (Q3 2025) and $48,000 (9M 2025) for clinical development-related services from Boston Image Reading Center LLC (BIRC), where Nadia Waheed, the company's Chief Medical Officer, is a Director.
• Recorded a net credit of $(121,000) (9M 2025) for fees and expenses related to services rendered by i2Vision, Inc., an entity affiliated with Jeffrey Heier, Chief Scientific Officer, and Peter Kaiser, Chief Development Officer. No services were provided in Q3 2025.
• Incurred fees of $1,080,000 (9M 2024) for legal services from Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale) while it was deemed a related party through March 31, 2024, due to Christopher White, former Chief Business Officer, being the brother of a partner.

Stakeholder Impact

• **Shareholders:** Experienced dilution from recent equity offerings but benefit from a significantly extended cash runway into 2028, reducing immediate financing risk. Potential for future value creation hinges on successful clinical trial outcomes for AXPAXLI and its commercialization.
• **Employees:** Benefit from continued investment in R&D and potential expansion of marketing teams, indicating job stability and growth opportunities. Stock-based compensation remains a significant component of overall compensation.
• **Customers (DEXTENZA):** Continued availability of DEXTENZA, with efforts to address reimbursement challenges and increase unit sales, aims to maintain and grow customer base.
• **Patients (Wet AMD, NPDR, OAG/OHT):** Potential for new, less frequent, and potentially superior treatment options with AXPAXLI and OTX-TIC, offering improved quality of life and disease management.
• **Creditors (Barings Finance LLC):** The company maintains a minimum liquidity covenant of $20.0 million and has pledged assets as collateral, providing a level of security for its debt obligations.

Next Steps

• Topline results for the SOL-1 trial (wet AMD) are expected in the first quarter of 2026.
• Topline data for the SOL-R trial (wet AMD) is on track for the first half of 2027.
• Initiate the long-term extension study of AXPAXLI for wet AMD (SOL-X trial).
• Imminently initiate two superiority registrational Phase 3 clinical trials of AXPAXLI for non-proliferative diabetic retinopathy (NPDR), referred to as the HELIOS-2 and HELIOS-3 trials.
• Evaluate next steps for the OTX-TIC program for open-angle glaucoma or ocular hypertension.
• Submit a New Drug Application (NDA) with the FDA for marketing approval of AXPAXLI for wet AMD, if favorable results are obtained from the SOL-1 and SOL-R trials.
• Continue to support the commercialization of DEXTENZA and initiate/continue marketing-related activities for the potential commercial launch of AXPAXLI.
• Continue to prosecute patents and patent applications for AXPAXLI and other product candidates and technologies globally.
• Evaluate the impact of recently issued accounting pronouncements (ASU No. 2025-06) on consolidated financial statements.

Key Dates

Recommendation

While Ocular Therapeutix has demonstrated significant progress in its clinical pipeline, particularly with AXPAXLI in wet AMD and NPDR, and has substantially bolstered its liquidity with a $445.4 million capital raise, the company continues to incur substantial operating losses. DEXTENZA's revenue decline, despite increased unit sales, highlights commercial challenges. The extended cash runway into 2028 is a critical positive, de-risking near-term funding needs. However, the company remains a clinical-stage entity with key data readouts (SOL-1 in Q1 2026, SOL-R in H1 2027) still in the future. The potential for AXPAXLI is high, but commercialization expenses are not yet fully factored into the cash runway. Given the mixed financial performance, strong pipeline progress, and improved but still finite liquidity, a 'hold' recommendation is appropriate. Investors should await further clinical data and clearer commercialization pathways for AXPAXLI before making more aggressive moves, while acknowledging the significant de-risking achieved through the recent financing.

Keywords

Ocular Therapeutix, AXPAXLI, wet AMD, NPDR, DEXTENZA, ELUTYX, ophthalmology, biopharmaceutical, clinical trials, Phase 3, SEC filing, 10-Q, capital raise, retinal disease, ocular inflammation, diabetic retinopathy, OAG, OHT, FDA, drug development